Multiple myeloma

Critical Reviews in Oncology/Hematology

Volumn 27, Issue 2, 1998, Pages 165-167

  Zulian, G B ^a   Babare, R ^b   Zagonel, V ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ERYTHROPOIETIN; IMMUNOGLOBULIN; MELPHALAN; PREDNISONE;

ANEMIA; HEMATOCRIT; HUMAN; HYPERCALCEMIA; INFECTION RISK; MULTIPLE MYELOMA; SHORT SURVEY;

EID: 0032006314     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)10030-0     Document Type: Article

References (14)

1. [1] Rinks RA, Smith AB, Hornung R, et al. Benzene and leukemia: an epidemiologic risk assessment. New Engl J Med 1987;316:1044-50.
2. [2] Crawford J, Eve MK, Cohen HJ. Evaluation of monoclonal gammapathies in the well elderly. Am J Med 1987;82:39-45.
3. [3] Kyle RA. Benign monoclonal gammopathy after 20 to 35 years of follow up. Mayo Clin Proc 1994;69:680-3.
4. [4] Lust JA. Role of cytokines in the pathogenesis of monoclonal gammopathies. Mayo Clin Proc 1993;68:26-36.
5. [5] Gautier M, Cohen HJ. Multiple myeloma in the elderly. J Am Geriatr Soc 1994;42:653-64.
6. [6] Ludwig H, Fritz E, Kotzmann H, et al. Erythropoietin treatment of anemia associated with multiple myeloma. New Engl J Med 1990;322:1693-9.
7. [7] Fleisch H. Biosphosphates. Pharmacology and use in the treatment of tumour-induced hypercalcaemia and metastatic bone disease. Drugs 1991;42:919-44.
8. [8] Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New Engl J Med 1996;334:488-93.
9. [9] Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New Engl J Med 1994;330:484-9.
10. [10] Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-42.
11. [11] Zulian GB. Multiple myeloma: Clinical evaluation of plasma cell lymphoproliferative disorders and initial management. Semin Hematol 1997;34 (Suppl 1):29-39.
12. [12] Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. New Engl J Med 1984;310:1353-6.
13. [13] Babare R, Zagonel V, Ferrara F, et al. Cost-benefit of chemotherapy on refractory-resistant multiple myeloma (MM): VAD versus VID combination. 19th Annual Meeting of ESMO, Lisboa. Ann Oncol 1994;5 (Suppl 8)(O628):125.
14. [14] Alexanian R, Dimopoulos MA, Delasalle K, et al. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:887-90.